Latest Advisory

  • FDA Advisory No. 2018-049 || Public Health Warning Against the Purchase and Consumption of the Following Unregistered Food Products and Food Supplements:

    FDA Advisory No. 2018-049 || Public Health Warning Against the Purchase and Consumption of the Following Unregistered Food Products and Food Supplements:

    Read more

  • FDA Advisory No. 2018-048 || Public Health Warning Against the Purchase and Consumption of the following Unregistered Food Products:

    FDA Advisory No. 2018-048 || Public Health Warning Against the Purchase and Consumption of the following Unregistered Food Products:

    Read more

  • FDA Advisory No. 2018-047 || ASEAN Advisory Statement on Talc

    FDA Advisory No. 2018-047 || ASEAN Advisory Statement on Talc

    Read more

  • FDA Advisory No. 2018-046 || Public Health Warning Against the Use of Unregistered Medical Device (Mersilk Black Braided Silk Suture N536)

    FDA Advisory No. 2018-046 || Public Health Warning Against the Use of Unregistered Medical Device (Mersilk Black Braided Silk Suture N536)

    Read more

  • FDA Advisory No. 2018-045 || Voluntary Product Recall of Guider Softip Guiding Catheter

    FDA Advisory No. 2018-045 || Voluntary Product Recall of Guider Softip Guiding Catheter

    Read more

  • FDA Advisory No. 2018-044 || VOLUNTARY RECALL OF THE MALECOT NEPHROSTOMY CATHETERS WITH PRODUCT REGISTRATION MDR NO. 02508

    FDA Advisory No. 2018-044 || VOLUNTARY RECALL OF THE MALECOT NEPHROSTOMY CATHETERS WITH PRODUCT REGISTRATION MDR NO. 02508

    Read more

  • FDA Advisory No. 2018-043 || VOLUNTARY RECALL OF INNOVA™ 180 mm & 200 mm SELF-EXPANDING STENT SYSTEM

    FDA Advisory No. 2018-043 || VOLUNTARY RECALL OF INNOVA™ 180 mm & 200 mm SELF-EXPANDING STENT SYSTEM

    Read more

  • FDA Advisory No. 2018-042 || Lifting the Advisory of LIPA YOUNG COCONUT WATER WITH COCONUT BITS under FDA Advisory No. 2016-071, Subject: “Public Health Warning Against the Use of the Following Unregistered Food Product: Lipa Fresh Buko Juice Young Coconu

    FDA Advisory No. 2018-042 || Lifting the Advisory of LIPA YOUNG COCONUT WATER WITH COCONUT BITS under FDA Advisory No. 2016-071, Subject: “Public Health Warning Against the Use of the Following Unregistered Food Product: Lipa Fresh Buko Juice Young Coconu

    Read more

  • FDA Advisory No. 2018-041 || Public Health Warning Against the Use of Unnotified Cosmetic Products (Batch 3)

    FDA Advisory No. 2018-041 || Public Health Warning Against the Use of Unnotified Cosmetic Products (Batch 3)

    Read more

  • FDA Advisory No. 2018-040 || Public Health Warning Against the Use of Unregistered Household/Urban Pesticide Products (Batch 3)

    FDA Advisory No. 2018-040 || Public Health Warning Against the Use of Unregistered Household/Urban Pesticide Products (Batch 3)

    Read more

  • FDA Advisory No. 2018-039 || Public Health Warning Against the Use of Cosmetic Products Containing Banned Ingredient/s (Batch 3)

    FDA Advisory No. 2018-039 || Public Health Warning Against the Use of Cosmetic Products Containing Banned Ingredient/s (Batch 3)

    Read more

  • FDA Advisory No. 2018-038 || Public Health Warning Against the Use of Cosmetic Products Containing Banned Ingredient/s (Batch 2)

    FDA Advisory No. 2018-038 || Public Health Warning Against the Use of Cosmetic Products Containing Banned Ingredient/s (Batch 2)

    Read more

  • FDA Advisory No. 2018-037 || Public Health Warning Against the Use of Counterfeit Cosmetic Products (Batch 1)

    FDA Advisory No. 2018-037 || Public Health Warning Against the Use of Counterfeit Cosmetic Products (Batch 1)

    Read more

  • FDA Advisory No. 2018-036-A || Babala sa Publiko Tungkol sa Pagbili at Paggamit ng Hindi Rehistradong Gamot na Hair Organics Ocara Hair Grower Hair Vitamins Gugo + Aloe Vera + Minoxidil Shampoo 150 mL.

    FDA Advisory No. 2018-036-A || Babala sa Publiko Tungkol sa Pagbili at Paggamit ng Hindi Rehistradong Gamot na Hair Organics Ocara Hair Grower Hair Vitamins Gugo + Aloe Vera + Minoxidil Shampoo 150 mL.

    Read more

  • FDA Advisory No. 2018-036 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product Hair Organics Ocara Hair Grower Hair Vitamins Gugo + Aloe Vera + Minoxidil Shampoo 150 mL.

    FDA Advisory No. 2018-036 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product Hair Organics Ocara Hair Grower Hair Vitamins Gugo + Aloe Vera + Minoxidil Shampoo 150 mL.

    Read more

  • FDA Advisory No. 2018-035-A || Babala sa Publiko Tungkol sa Pagbili at Paggamit ng mga Hindi Rehistradong Gamot:

    FDA Advisory No. 2018-035-A || Babala sa Publiko Tungkol sa Pagbili at Paggamit ng mga Hindi Rehistradong Gamot:

    Read more

  • FDA Advisory No. 2018-035 || Public Health Warning Against the Purchase and Use of the Following Unregistered  Drug Products:

    FDA Advisory No. 2018-035 || Public Health Warning Against the Purchase and Use of the Following Unregistered Drug Products:

    Read more

  • FDA Advisory No. 2018-034 || Reiteration of Grace Periods Given to the Cosmetic Industry for Ingredients Banned or Restricted During the Recent ASEAN Cosmetic Committee (ACC) Meetings and Its Related Events

    FDA Advisory No. 2018-034 || Reiteration of Grace Periods Given to the Cosmetic Industry for Ingredients Banned or Restricted During the Recent ASEAN Cosmetic Committee (ACC) Meetings and Its Related Events

    FDA Advisory No. 2018-034

    Reiteration of Grace Periods Given to the Cosmetic Industry for Ingredients Banned or Restricted During the Recent ASEAN Cosmetic Committee (ACC) Meetings and Its Related Events 

    In the interest of public service and in line with the Food and Drug Administration’s (FDA’s) thrust to strengthen its enforcement of existing rules, regulations and standards, the Center for Cosmetics Regulation and Research (CCRR) hereby reiterates the impending end of the grace periods given to the cosmetic industry through FDA Circulars No.  2017-006 and 2017-007 for newly banned ingredients or ingredients with new restrictions adopted during the 25th and 26th ASEAN Cosmetic Committee (ACC) meetings and its related events.

    • FDA Circular No. 2017-006 “Updates and Amendments of the ASEAN Cosmetic Directive as Adopted During the 25th ASEAN Cosmetic Committee Meeting and Its Related Events

    ACD Annex and Reference No.

    Chemical / Substance

    Maximum Authorized Concentration and/or Other Limitations and Requirements

    Grace Period

    Annex III Ref. No. 15d

    Potassium Hydroxide

    1.5% as callosity softener / remover

    Conditions of use and warning which must be printed on the label:

    ·         Contains alkali.

    ·         Avoid contact with eyes

    ·         Keep out of reach of children

    ·         Read directions for use carefully

    31 August 2018

    Annex IV Color Index (CI) 77266

    Carbon Black

    Additional Restriction/Conditions of Use:

    Purity >97 %, with the following impurity profile: Ash content ≤ 0.15%, total sulphur ≤ 0.65%, total PAH ≤500 ppb and benzo(a)pyrene ≤ 5ppb, dibenz(a,h)anthracene ≤5 ppb, total As ≤3 ppm, total Pb ≤10 ppm, total Hg ≤ 1ppm.

    31 August 2018

    Annex IV CI 77266 (nano)

    Carbon Black (Nano)

    10%

    Not to be used in applications that may lead to exposure of the end user's lungs by inhalation.

    Only nanomaterials having the following characteristics are allowed:

    — Purity >97%, with the following impurity profile: Ash content ≤0.15%, total sulphur ≤0.65%, total PAH ≤500 ppb and benzo(a)pyrene ≤5 ppb, dibenz(a,h)anthracene ≤5 ppb, total As ≤3 ppm, total Pb ≤10 ppm, and total Hg ≤1 ppm;

    — Primary particle size ≥20 nm.

    31 August 2018

    Annex VI Ref. No. 57

    2-Methyl-2H-isothiazol- 3-one

     

    Methylisothiazolinone

    0.01%

    Allowed to be used only in rinse-off products.

    Prohibited in leave-on products.

    31 August 2018

    Annex VII Ref. No. A29

    Zinc Oxide

     

    Additional Restriction/Conditions of Use:

    “Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation.”

    31 August 2018

    Annex VII Ref. No. A29a

    Zinc Oxide (nano)

    25%1

    Not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation.

    Only nanomaterials having the following characteristics are allowed:

    -          purity ≥96% with wurtzite crystalline structure and physical appearance as clusters that are rod-like, star-like and/or isometric shapes, with impurities consisting only of carbon dioxide and water whilst other impurities are less than 1% in total.

    -          Median diameter of the particle number size distribution D50 (50% of the number below this diameter) >30 nm and D1 (1% below this size) >20nm.

    -          Water solubility <50 mg/l.

    -          Coating materials can be used that have been demonstrated to be safe and not to affect the nanoparticle properties related to the behaviour and/or effects2

    31 August 2018

    Annex VII Ref. No. 27a

    Titanium Dioxide (nano)

    25%3

    Not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation.

    Only nanomaterials having the following characteristics are allowed:

    - Purity ≥99%

    - Rutile form, or rutile with up to 5% anatase, with crystalline structure and physical appearance as clusters of spherical, needle, or lanceolate shapes,

    - Median particle size based on number size distribution ≥30 nm,

    - Aspect ratio from 1 to 4.5 and volume specific surface area ≤460 m2/cm3,

    - Coating materials can be used that have been demonstrated to be safe and not to affect the nanoparticle properties related to the behaviour and/or effects4

    - Photocatalytic activity ≤ 10% compared with corresponding non-coated or non-doped reference,

    - Nanoparticles are photostable in the final formulation.

    31 August 2018

     

    1 In case of combined use of Zinc Oxide and Zinc Oxide (nano), the sum shall not exceed the maximum authorized concentration which is 25%.

    2The amendment to the original restriction on the coating material for Zinc Oxide (nano) is adopted during the 26th ACC Meeting and its related events and disseminated through FDA Circular No. 2017-007.

    3 In case of combined use of Titanium Dioxide and Titanium Dioxide (nano), the sum shall not exceed the maximum authorized concentration which is 25%.

    4The amendment to the original restriction on the coating material for Titanium Dioxide (nano) is adopted during the 26th ACC Meeting and its related events and disseminated through FDA Circular No. 2017-007.

    • FDA Circular No. 2017-007 “Updates and Amendments of the ASEAN Cosmetic Directive as Adopted During the 26th ASEAN Cosmetic Committee Meeting (ACC) and Its Related Events

    ACD Annex and Reference No.

    Chemical / Substance

    Maximum Authorized Concentration and/or Other Limitations and Requirements

    Grace Period

    Annex III Ref. No. 312

    Diethylene Glycol Monoethyl Ether (DEGEE)

     

    Ethoxydiglycol

    a.       Oxidative hair dye products – 7%

    b.       Non-oxidative hair dye products – 5%

    c.        Rinse-off products other than hair dye products – 10%

    d.       Other non-spray cosmetic products – 2.6%

    e.        The following spray products: fine fragrances, hair sprays, anti-perspirants and deodorants – 2.6%

     

    (a) to (e) The level of ethylene glycol impurity in Ethoxydiglycol must be ≤0.1 %

    Not to be used in eye products and oral products.

    01 December 2018

    Annex III Ref. No. 313

    Polidocanol

     

    Laureth-9

     

    a.       Leave-on products – 3.0%

    b.       Rinse-off products – 4.0%

    01 December 2018

    Annex III

    Hair Dye Entries

    Additional conditions of use and warning which must be printed on the label:

    Do not use to dye eyelashes or eyebrows

    01 June 2018

    Annex VII Ref. No. 4

    Oxybenzone (INN)

    6%

     

    Conditions of use and warning which must be printed on the label:

    Contains oxybenzone

     

    01 December 2018

    Cosmetic establishments are strongly advised to recall their products containing the abovementioned ingredients whose use is outside the new restrictions and conditions laid down in the ASEAN Cosmetic Ingredient Annexes by the end of the grace period. Violation of the new restrictions and conditions after the grace period has ended shall subject the violator to appropriate regulatory actions.

    For more information, cosmetic establishments may check the FDA website (www.fda.gov.ph) for updates and amendments to the ASEAN Cosmetic Directive (ACD), its annexes and appendices.

    Dissemination of the information to all concerned is requested.

    Read more

  • FDA Advisory No. 2018-033 || Public Health Warning Against the Purchase and Consumption of the following Unregistered Food Products:

    FDA Advisory No. 2018-033 || Public Health Warning Against the Purchase and Consumption of the following Unregistered Food Products:

    Read more

  • FDA Advisory No. 2018-032 || Public Health Warning Against the Purchase and Consumption of the following Unregistered Food Products:

    FDA Advisory No. 2018-032 || Public Health Warning Against the Purchase and Consumption of the following Unregistered Food Products:

    Read more

Postponement of the Conduct of Pharmacovigilance Regulations and Guidelines for PV Office Seminar

Please be informed that the conduct of the Pharmacovigilance Regulations and Guidelines for PV Office Seminar on 12-13 October, is POSTPONED and moved to 15-16 November 2017, due to non-availability of resource speakers from the Center for Drug Regulation and Research

Attachments:
Download this file (Announcement.pdf)Announcement.pdf

FDA Circular No. 2017-011 

New Batch Notification Form and Procedure

 

I. RATIONALE

  Pursuant to Section 5 (Reengineering of Systems and Procedures) of Republic Act No. 9485, otherwise known as the Anti-Red Tape Act of 2007, All offices and agencies which provide frontline services are hereby mandated to regularly undertake time and motion studies, undergo evaluation and improvement of their transaction systems and procedures and re-engineer the same if deemed necessary to reduce bureaucratic red tapeand processing time".

Period to Accept Petitions/Oppositions Relative to the Recertification of Contraceptive Products Ended Last 31 August 2017

On 21 August 2017, FDA issued Advisory No. 2017-253 to formally begin the recertification process. 

FDA Advisory No. 2017-253 opened to the public the details of the contraceptive products subject to recertification and provided the mechanics for submitting petitions and corresponding evidence on their abortifacient or non-abortifacient properties. 

Also provided in FDA Advisory No. 2017-253 is the deadline for their submission which is ten (10) calendar days from the date of posting and publication.  Said Adivsory was posted at the FDA’s website, www.fda.gov.ph, on 21 August 2017 and published in 2 newspapers of general circulation, namely, The Philippine Star and the Manila Times, on 21 August 2017.  

August 31 marks the tenth day of the posting and publication of FDA Advisory No. 2017-253.   

FDA hereby formally concludes the submission period and will proceed with the review phase of the recertification process taking due consideration of the petitions submitted and their supporting evidence.

FDA Circular No. 2017-010

Subject:  New Collection Policy and Procedure

I. Rationale

Republic Act No. 9485, also known as Anti-Red Tape Act of 2007, was enacted to improve efficiency in the delivery of government service to the public and to establish effective practices aimed at the prevention of graft and corruption. This law mandates all government agencies and officers to take appropriate measures to promote transparency with regard to the manner of transacting with the public

to continue reading download attachment...

 

Compliance with the Supreme Court Resolution Regarding the Recertification and Certification of Contraceptive Products

On 26 April 2017, the Supreme Court (SC) issued a Resolution ordering the Food and Drug Administration (FDA) to consider “the oppositions filed by Alliance for the Family Foundation, Inc. (ALFI) with respect to the listed drugs, including Implanon and Implanon NXT, based on the standards of the Reproductive Health Law, as construed in Imbong vs. Ochoa, and to decide the case within sixty (60) days from the date it will be deemed submitted for resolution”. 

Consequently, the FDA issued on 21 August 2017 Advisory No. 2017-253 to begin the recertification process for the listed products. 

FDA wishes to advice the public that—  

1) For the recertification process, the FDA will no longer issue any additional guidelines as the provisions in RA 10354 and its Implementing Rules and Regulations, and the decision of the High Court in ALFI vs. Garin et al. are already clear. 

2) For the certification process of new reproductive health products, the draft of the revised IRR will contain the guidelines that will be implemented by the FDA in the registration process. As a matter of procedure, a public consultation will be scheduled and held to give opportunity to the public to comment on this. 

The FDA is determined to do its part by exerting all efforts to consider the oppositions filed and decide on their merits accordingly.

The FDA is mindful of its responsibility to comply with the SC’s decision, and to uphold the mandates of due process, both geared towards the goal of ensuring and protecting public health.

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter